|1.||Fink, Gregory D: 26 articles (01/2015 - 02/2002)|
|2.||Watts, Stephanie W: 23 articles (03/2015 - 02/2002)|
|3.||Galligan, James J: 18 articles (10/2013 - 02/2002)|
|4.||Brown, Lindsay: 14 articles (01/2016 - 02/2002)|
|5.||Schiffrin, Ernesto L: 12 articles (07/2013 - 02/2002)|
|6.||Chen, Alex F: 10 articles (05/2012 - 02/2002)|
|7.||Luft, Friedrich C: 9 articles (03/2013 - 08/2002)|
|8.||Kim, Soo Wan: 9 articles (01/2013 - 04/2002)|
|9.||Ndisang, Joseph Fomusi: 8 articles (01/2015 - 06/2008)|
|10.||Harrison, David G: 8 articles (06/2012 - 04/2003)|
|1.||Hypertension (High Blood Pressure)
03/01/2015 - "DOCA-salt treatment did not increase the protein levels of ER stress and autophagy markers in NT mice, despite a significant increase in BP. In addition, these markers were not affected by hACE2 overexpression in the brain, despite a significant reduction of hypertension in SL mice. "
12/08/2011 - "Treatment with compound 3 or 4 resulted in a significant reduction or attenuation of blood pressure in an established or developing model of hypertension, deoxycorticosterone acetate-treated rats. "
01/02/2008 - "Following the development of hypertension, GluR1 spine and puncta counts were significantly greater in DOCA-salt rats than controls. "
01/01/1986 - "Vasoconstrictor responses to the electrical nerve stimulation were significantly greater in DOCA-salt hypertension in the chronic phase than the age-matched normotensive controls. "
06/01/1990 - "The results of this study indicate that only the combination of 1% NaCl in tap water and DOCA administration is effective in accelerating hypertension in adult SHR. "
07/01/2015 - "In contrast, DOCA-salt hypertensive rats treated with different dose of GSPE or ALM showed a significant improvement of renal injury with decreased urine protein, KW/BW, degree of renal fibrosis, renal total MDA and Hyp contents compared to the untreated group. "
01/01/2014 - "Thus, During myocardial fibrosis of DOCA induced salt-sensitive hypertensive rats, PDGFRα acts at early stage, but PDGFRβ functions in the whole process. "
01/01/2014 - "The severity of myocardial fibrosis and PVCA/VA ratio in DOCA+IMA group were markedly lower than those in DOCA group although they were higher than those in CON group. "
01/01/2014 - "At days 28, the severity of myocardial fibrosis and PVCA/VA ratio in DOCA group were significantly increased when compared with CON group. "
01/01/2014 - "Role of PDGFs/PDGFRs signaling pathway in myocardial fibrosis of DOCA/salt hypertensive rats."
|3.||Cardiomegaly (Heart Hypertrophy)
08/01/2009 - "After 6 weeks DOCA, Gas 6(-/-) mice developed similar telemetric blood pressure elevations compared to wild-type mice but were protected from cardiac hypertrophy. "
09/01/2002 - "The DOCA and DOCA+L-NAME groups showed relative renal and cardiac hypertrophy, which was not observed in the DOCA+L-NAME+prazosin group. "
08/01/2002 - "In addition, DOCA-salt treatment alters the amounts of Kv transcripts independently to cardiac hypertrophy, suggesting that the mineralocorticoid may be involved in Kv gene expression."
01/01/1998 - "ET-1 may not play a critical role in the pathophysiology of the severe concentric cardiac hypertrophy present in DOCA-salt hypertensive rats."
11/01/1997 - "These findings report for the first time the cardiac cell-specific implication of Ang II and the intracellular calcium signaling pathway stimulated by the AT1 receptor in cardiac hypertrophy in DOCA-salt-hypertensive rats."
04/01/1996 - "A marked decrease in vascular wall hypertrophy was observed in the FR139317-treated DOCA-salt rats. "
01/01/2016 - "Mal C exerts anti-hypertensive property in DOCA-salt rats by reducing oxidative stress and organ hypertrophy, and improving endothelial and vascular functions. "
11/01/2015 - "Urinary excretion of deoxycorticosterone was higher in 11βHSD1 knockout mice, and there was hypertrophy of cells in the zona fasciculata of the adrenal cortex. "
08/01/2015 - "In conclusion, Ang-(1-7) protective signaling against DOCA-induced diastolic dysfunction occurs independently of BP attenuation and is mediated by the activation of pathways involved in Ca(2+) handling, hypertrophy, and survival. "
09/01/2011 - "EO significantly decreased arterial blood pressure and heart rate along with cardiac and renal hypertrophy in a dose-dependent fashion as compared to DOCA control rats. "
|5.||Ganglion Cysts (Ganglion)
12/01/2001 - "We found deoxycorticosterone-salt and stroke prone-spontaneously hypertensive rats to exhibit a decreased erectile response, recorded as intracavernosal pressure/mean arterial pressure (ICP/MAP) upon electrical stimulation of the major pelvic ganglion. "
06/01/2003 - "Likewise, both maximal percentage and absolute decreases in MAP elicited by i.v. injection of the ganglion blocker, hexamethonium (30 mg/kg), were significantly greater in DOCA-salt hypertensive than in control rats. "
12/01/2002 - "Likewise, both maximal percent and absolute decreases in MAP elicited by i.v. injection of the ganglion blocker, hexamethonium (30 mg/kg body wt.), were significantly greater in DOCA-salt-hypertensive than in control rats. "
03/01/2000 - "Likewise, both maximal percent and absolute decreases in MAP elicited by i.v. hexamethonium (30 mg/kg), a ganglion blocker, were significantly greater in DOCA-salt hypertensive than in control rats. "
01/01/1987 - "Also, DOCA-salt rats had increased depressor response to hexamethonium bromide, a ganglion blocker. "
|2.||Messenger RNA (mRNA)
|3.||Hexamethonium (Hexamethonium Bromide)
|4.||Collagen Type I (Type I Collagen)
|5.||Ascorbic Acid (Vitamin C)
|7.||candesartan cilexetil (Amias)
|3.||Surgical Instruments (Clip)